Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 44% Improvement Relative Risk Mortality (b) 66% Mortality (c) 62% Mortality (d) -60% Mortality, day 14 31% Mortality, day 10 35% Mortality, day 7 48% Mortality, day 5 35% Mortality, day 3 13% Remdesivir for COVID-19  Madan et al.  LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 658 patients in India Lower mortality with remdesivir (p=0.035) c19early.org Madan et al., medRxiv, July 2021 Favors remdesivir Favors control

Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir

Madan et al., medRxiv, doi:10.1101/2021.07.15.21260600
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Retrospective 1,262 hospitalized patients, 398 treated with remdesivir, showing unadjusted lower mortality with treatment, and a treatment delay-response relationship.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
risk of death, 44.4% lower, RR 0.56, p = 0.03, treatment 23 of 398 (5.8%), control 27 of 260 (10.4%), NNT 22, unadjusted.
risk of death, 65.6% lower, RR 0.34, p = 0.04, treatment 4 of 112 (3.6%), control 27 of 260 (10.4%), NNT 15, unadjusted, <5 days from onset.
risk of death, 61.7% lower, RR 0.38, p = 0.009, treatment 9 of 226 (4.0%), control 27 of 260 (10.4%), NNT 16, unadjusted, 5-10 days from onset.
risk of death, 60.5% higher, RR 1.60, p = 0.18, treatment 10 of 60 (16.7%), control 27 of 260 (10.4%), unadjusted, >10 days from onset.
risk of death, 31.0% lower, RR 0.69, p = 0.30, treatment 19 of 398 (4.8%), control 18 of 260 (6.9%), NNT 47, day 14.
risk of death, 34.7% lower, RR 0.65, p = 0.32, treatment 14 of 398 (3.5%), control 14 of 260 (5.4%), NNT 54, day 10.
risk of death, 47.7% lower, RR 0.52, p = 0.22, treatment 8 of 398 (2.0%), control 10 of 260 (3.8%), NNT 54, day 7.
risk of death, 34.7% lower, RR 0.65, p = 0.53, treatment 5 of 398 (1.3%), control 5 of 260 (1.9%), NNT 150, day 5.
risk of death, 12.9% lower, RR 0.87, p = 1.00, treatment 4 of 398 (1.0%), control 3 of 260 (1.2%), NNT 672, day 3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Madan et al., 19 Jul 2021, retrospective, India, preprint, 22 authors.
This PaperRemdesivirAll
Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir
Dr Surabhi Madan, Amit Patel, Kartikae Sharan, Shayon Ghosh, Vishnu Venugopal, Nitesh Shah, Bhagyesh Shah, Vipul Thakkar, Rashmi Chovatiya, Hardik Shah, Pradip Dabhi, Minesh Patel, Bhowmik Meghnathi, Vineet Sankhla, Vipul Kapoor, Tejas Patel, Maulik Soni, Nirav Bapat, Kaivan Shah, Ritanshu Chandarana, Parloop Bhatt, Manish Rana
doi:10.1101/2021.07.15.21260600
Background: Remdesivir (RDV) in coronavirus disease 2019 has been found to be beneficial in patients with severe disease; however, its role in mild-moderate disease and its optimal timing need to be identified. Objective: To assess the course of illness and final outcome in patients who received RDV at various stages of illness, and compare it to the non-RDV group. Methods: This is a retrospective data analysis of 1262 COVID-19 patients hospitalized from May5, 2020 to August 31, 2020. The primary outcomes were progression to mechanical ventilation (MV) or death. Kaplan Meier survival analysis and log rank test were used for evaluating primary outcomes. Results: 398 patients comprised the RDV group and 260 patients comprised the non-RDV group. 2/3 rd of patients were above 50 years of age in both the groups and 3/4 th patients were male. Mortality rate was 5.8% in RDV group (10.4% in non-RDV group). Mortality rate was 3.6%, 4% and 16.7% when RDV was started within 5 days, 5 to 10 days and after 10 days of symptom onset respectively. Fewer patients in RDV group progressed to MV (4.0% v/s 8.2%). Earlier discharge occurred in RDV group. Use of supplemental oxygen was observed in 44.7% patients in RDV group (54.2% in non-RDV group). No significant adverse events were observed with RDV. Survival analysis showed that probability of event (death) was significant for patients with hypertension (HT) and/or diabetes mellitus (DM) in RDV group. Conclusion: Early initiation of RDV is associated with shorter hospital stay, lower mortality as well as reduced need for supplemental oxygen and mechanical ventilation. .
References
Adamsick, Gandhi, Bidell, Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19, J Am Soc Nephrol
Beigel, Tomashek, Dodd, Remdesivir for the Treatment of COVID-19-Final Report, N Engl J Med, doi:10.1056/NEJMoa2007764
Cantini, Goletti, Petrone, Immune therapy, or Antiviral Therapy, or Both for COVID-19; A systematic review, Drugs, doi:10.1007/s40265-020-01421-w
Ng Deborah, Chiaw Yee, Chan, Fever Patterns, Cytokine Profiles, and Outcomes in COVID-19, Open Forum Infect Dis, doi:10.1093/ofid/ofaa375.eCollection2020
Oleander, Perez, Go, Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care, Clin Infect Dis, doi:10.1093/cid/ciaa1041
Spinner, Gottlieb, Criner, Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19, A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2020.16349
Thakare, Gandhi, Modi, Safety of Remdesivir in Patients With Acute Kidney Injury or CKD, Kidney Int Rep
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
{ 'DOI': '10.1101/2021.07.15.21260600', 'URL': 'http://dx.doi.org/10.1101/2021.07.15.21260600', 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Remdesivir ' '(RDV) in coronavirus disease 2019 (COVID-19) has been found to be beneficial in patients with ' 'severe disease; however, its role in mild-moderate disease and its optimal timing need to be ' 'identified.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To assess ' 'the course of illness and final outcome in patients who received RDV at various stages of ' 'illness, and compare it to the non-RDV ' 'group.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This is a ' 'retrospective data analysis of 1262 COVID-19 patients hospitalized from May5, 2020 to August ' '31, 2020. The primary outcomes were progression to mechanical ventilation (MV) or death. ' 'Kaplan Meier survival analysis and log rank test were used for evaluating primary ' 'outcomes.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>398 patients ' 'comprised the RDV group and 260 patients comprised the non-RDV group. ' '2/3<jats:sup>rd</jats:sup> of patients were above 50 years of age in both the groups and ' '3/4<jats:sup>th</jats:sup> patients were male. Mortality rate was 5.8% in RDV group (10.4% in ' 'non-RDV group). Mortality rate was 3.6%, 4% and 16.7% when RDV was started within 5 days, 5 ' 'to 10 days and after 10 days of symptom onset respectively. Fewer patients in RDV group ' 'progressed to MV (4.0% v/s 8.2%). Earlier discharge occurred in RDV group. Use of ' 'supplemental oxygen was observed in 44.7% patients in RDV group (54.2% in non-RDV group). No ' 'significant adverse events were observed with RDV. Survival analysis showed that probability ' 'of event (death) was significant for patients with hypertension (HT) and/or diabetes mellitus ' '(DM) in RDV ' 'group.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Early ' 'initiation of RDV is associated with shorter hospital stay, lower mortality as well as ' 'reduced need for supplemental oxygen and mechanical ventilation.</jats:p></jats:sec>', 'accepted': {'date-parts': [[2021, 7, 19]]}, 'author': [ {'affiliation': [], 'family': 'Madan', 'given': 'Surabhi', 'sequence': 'first'}, {'affiliation': [], 'family': 'Patel', 'given': 'Amit', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sharan', 'given': 'Kartikae', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Ghosh', 'given': 'Shayon', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Venugopal', 'given': 'Vishnu', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Shah', 'given': 'Nitesh', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Shah', 'given': 'Bhagyesh', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Thakkar', 'given': 'Vipul', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Chovatiya', 'given': 'Rashmi', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Shah', 'given': 'Hardik', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Dabhi', 'given': 'Pradip', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Patel', 'given': 'Minesh', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Meghnathi', 'given': 'Bhowmik', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sankhla', 'given': 'Vineet', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Kapoor', 'given': 'Vipul', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Patel', 'given': 'Tejas', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Soni', 'given': 'Maulik', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bapat', 'given': 'Nirav', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Shah', 'given': 'Kaivan', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Chandarana', 'given': 'Ritanshu', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bhatt', 'given': 'Parloop', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Rana', 'given': 'Manish', 'sequence': 'additional'}], 'container-title': [], 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2021, 7, 19]], 'date-time': '2021-07-19T21:20:20Z', 'timestamp': 1626729620000}, 'deposited': { 'date-parts': [[2021, 7, 21]], 'date-time': '2021-07-21T08:15:51Z', 'timestamp': 1626855351000}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'indexed': {'date-parts': [[2022, 4, 5]], 'date-time': '2022-04-05T02:59:57Z', 'timestamp': 1649127597081}, 'institution': [{'name': 'medRxiv'}], 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2021, 7, 19]]}, 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.07.15.21260600', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '246', 'original-title': [], 'posted': {'date-parts': [[2021, 7, 19]]}, 'prefix': '10.1101', 'published': {'date-parts': [[2021, 7, 19]]}, 'publisher': 'Cold Spring Harbor Laboratory', 'reference': [ { 'key': '2021072101150660000_2021.07.15.21260600v1.1', 'unstructured': 'Weekly epidemiological update on COVID-19 - 6 July 2021, Edition 47, 6 ' 'July 2021, Emergency Situational Updates, Weekly epidemiological update ' 'on COVID-19 - 6 July 2021 (who.int)'}, { 'DOI': '10.1007/s40265-020-01421-w', 'doi-asserted-by': 'crossref', 'key': '2021072101150660000_2021.07.15.21260600v1.2', 'unstructured': 'Cantini F , Goletti D , Petrone L et al. Immune therapy, or Antiviral ' 'Therapy, or Both for COVID-19; A systematic review. Drugs, October ' '2020.https://doi.org/10.1007/s40265-020-01421-w'}, { 'DOI': '10.1038/s41422-020-0282-0', 'doi-asserted-by': 'publisher', 'key': '2021072101150660000_2021.07.15.21260600v1.3'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.4', 'unstructured': 'FDA’ s approval of Veklury (remdesivir) for the treatment of COVID-19 – ' 'The Science of Safety and Effectiveness. Available from: ' 'https://www.fda.gov/drugs/drug-safety-and-availability/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.5', 'unstructured': 'World Health Organization. Therapeutics and COVID-19: living guideline. ' 'https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2, ' '6 July 2021, COVID-19: Clinical care'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.6', 'unstructured': 'National Institutes of Health. Coronavirus Disease 2019 (COVID-19) ' 'Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/ ' '(Accessed on May 27, 2021).'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.7', 'unstructured': 'Infectious Diseases Society of America Guidelines on the Treatment and ' 'Management of Patients with COVID-19 ' 'https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ ' '(Accessed on February 21, 2021).'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.8', 'unstructured': 'Clinical management protocol: COVID-19, Government of india ministry of ' 'health and family welfare, directorate general of health services, (emr ' 'division), version 5, 03.07.20.'}, { 'DOI': '10.1056/NEJMoa2007764', 'doi-asserted-by': 'publisher', 'key': '2021072101150660000_2021.07.15.21260600v1.9'}, { 'DOI': '10.1093/cid/ciaa1041', 'doi-asserted-by': 'crossref', 'key': '2021072101150660000_2021.07.15.21260600v1.10', 'unstructured': 'Oleander SA , Perez KK , Go AS , et al. Remdesivir for Severe ' 'Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard ' 'of Care. Clin Infect Dis 2020. Available from: ' 'https://doi.org/10.1093/cid/ciaa1041'}, { 'DOI': '10.1001/jama.2020.16349', 'doi-asserted-by': 'publisher', 'key': '2021072101150660000_2021.07.15.21260600v1.11'}, { 'DOI': '10.1016/S0140-6736(20)31022-9', 'doi-asserted-by': 'publisher', 'key': '2021072101150660000_2021.07.15.21260600v1.12'}, { 'DOI': '10.1093/ofid/ofaa375', 'doi-asserted-by': 'publisher', 'key': '2021072101150660000_2021.07.15.21260600v1.13'}, { 'DOI': '10.1681/ASN.2020050589', 'doi-asserted-by': 'publisher', 'key': '2021072101150660000_2021.07.15.21260600v1.14'}, { 'DOI': '10.1016/j.ekir.2020.10.005', 'article-title': 'Safety of Remdesivir in Patients With Acute Kidney Injury or CKD', 'doi-asserted-by': 'crossref', 'first-page': '206', 'journal-title': 'Kidney Int Rep', 'key': '2021072101150660000_2021.07.15.21260600v1.15', 'volume': '6', 'year': '2021'}, { 'DOI': '10.1056/NEJMoa2023184', 'doi-asserted-by': 'publisher', 'key': '2021072101150660000_2021.07.15.21260600v1.16'}, { 'key': '2021072101150660000_2021.07.15.21260600v1.17', 'unstructured': 'Gilead’ s Veklury® (Remdesivir) Associated With a Reduction in Mortality ' 'Rate in Hospitalized Patients With COVID-19 Across Three Analyses of ' 'Large Retrospective Real-World Data Sets. Available from: Gilead’ s ' 'Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in ' 'Hospitalized Patients With COVID-19 Across Three Analyses of Large ' 'Retrospective Real-World Data Sets | Business Wire'}], 'reference-count': 17, 'references-count': 17, 'relation': {}, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2021.07.15.21260600'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subtitle': [], 'subtype': 'preprint', 'title': 'Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients ' 'treated with and without Remdesivir', 'type': 'posted-content'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit